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After a short course of tacrolimus, Lewis rat liver 
allografts induce donor-specific nonreactivity in 
Brown Norway recipients that is immunosuppression-
independent after 28 days. To clarify the role of donor 
major histocompatibility complex (MIle) class II'" 
cells, we investigated the migration to the recipient 
splenic T- and B-cell compartments of different sub-
sets of Lewis MIle class II'" passenger leukocytes. The 
rise and decline of immune activation were monitored 
in the hepatic allograft and in the host spleen by anal-
yses of BrdU'" (proliferating) leukocytes, TUNEL + (ap-
optotic) cells, apoptosis-associated molecules, THlI 
TH2 cytokine profiles, and histoimmunocytochemical 
examination of graft and splenic tissues. Serial flow . 
cytometry studies during the 28-day period of drug-
assisted "hepatic tolerogenesis" showed that migra-
tory MIle class II+ cells accounted for less than half of 
the donor cells in the host spleen. The class II+ cells 
consisted mostly ofB cells that homed to splenic B-cell 
follicles with only a sp8J."Se representation of dendritic 
cells that were exclusively found in the splenic peri-
arteriolar lymphoid sheath. In parallel studies, trans-
plantation of the less tolerogenic heart produced a 
diminutive version of the same events, but with far 
fewer donor cells in the host spleen, evidence of sus-
tained immune activation, and the development of 
chronic rejection by 100 days. The data are consistent 
with the paradigm that migration of donor leukocytes 
is the prime determinant of variable tolerance induc-
tion induced by transplantation of the liver and other 
organs, but without regard for donor MIle class 11+ 
expression. 
INTRODUCTION 
It has been described (1, 2) how organ alloengraftment 
occurs as the result of "responses of co-existing donor, that is, 
passenger leukocytes, and recipient immune cells, each to the 
other, causing reciprocal clonal expansion followed by periph-
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eral clonal exhaustion" (3, 4). The persistence in the host of 
donor passenger leukocytes above some threshold required to 
maintain the clonal exhaustion-deletion induced acutely by 
the migratory donor cells is a necessary condition for long 
organ allograft survival (1-5). The variable deletional toler-
ance of the double-immune response evolves spontaneously 
in some experimental models (6-9), especially when the 
transplanted organ is the liver (6, 7, 10, 11). Immunosup-
pression usually is required to prevent one immune cell pop-
ulation from destroying the other before the reciprocal dele-
tion can occur. 
This paradigm has been controversial (12-15), in part be-
cause it is incompatible with numerous competing hypothe-
ses of organ engraftment (1, 2). For example-, the migratory 
donor cells found in recipient tissues early and late after 
organ transplantation include major histocompatibility com-
plex (MHC) class II'" dendritic cells (DC) (3-5, 11, 16-18) 
that have been associated historically with protective immu-
nity (that is, rejection) rather than immune nonreactivity or 
tolerance (19-22). We studied the donor MHC class II+ cells 
in a rat liver transplant model in which donor-specific toler-
ance develops over a period of 1 month under an umbrella of 
tacrolimus (TAC) immunosuppression. In addition to serial 
donor leukocyte determinations in the liver allograft and 
host spleen during the 4-week period of tolerogenesis, cyto-
kine and other parameters that reflect the rise and decline of 
immune activation were analyzed in the same locations. 
When appropriate, the findings were compared with those 
after transplantation ofthe less tolerogenic heart under iden-
tical treatment conditions. The results undermine the widely 
held view that the expression (or nonexpression) of MHC 
class II of the migratory donor leukocytes is a crucial deter-
minant of outcome after organ transplantation. 
MATERIALS AND METHODS 
Animals and Transplantation Procedures 
Male Lewis (LEW, RT11) and Brown Norway (EN, RTl n) rats 
weighing 150-250 g (Harlan Sprague Dawley, Indianapolis, IN) 
were maintained in a specific pathogen-free environment at the 
University of Pittsburgh and used as donors and recipients, respec-
tively. Heterotopic abdominal heart transplantation (HTx) and or-
thotopic liver transplantation (OLTx) (portal revascularization only) 
were carried out as previously described (5), according to the guide-
lines of the Council on Animal Care at the University of Pittsburgh. 
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Immunosuppression 
The naive BN heart and liver recipients were administered TAC 
(FK 506, Fujisawa Pharmaceutical Co., Osaka, Japan) at a daily 
intramuscular (lM) dose of 1.0 mg/kg on days 0-13, with single 
supplemental injections of the same dose on days 20 and 27. 
Experimental Design 
Cohorts of recipients were killed and autopsied on posttransplant 
days 1, 3, 5, 7, 14, and 28. The allograft and the host spleen were 
sectioned and fixed in 10% neutral-buffered formalin for routine 
histopathology, embedded in optimum cold temperature compound 
(Tissue-Tek, Ames Division, Miles Laboratories, Inc., Elkhart, IN) 
for immunohistochemical studies, and snap-frozen in liquid nitrogen 
for mRNA extraction. In addition, recipient spleen was used for flow 
cytometry. Several heart and liver recipients were kept for 100 days 
and killed for histopathological analysis of chronic rejection (CR) in 
the allografts and for collection of cervical lymph nodes for mixed 
lymphocyte reaction (MLR) assays. 
Routine Histopathology of Allografts 
Formalin-fixed heart and liver allografts were embedded in par-
affin, sectioned at 4 J1.ill, and stained with hematoxylin-eosin. In 
heart allografts, the overall severity of inflammation in the endocar-
dium, pericardium, interstitium, and periarterial spaces was semi-
quantitatively graded on the scale of 0-4 as none, minimal, mild, 
moderate, or severe (23). Arterial alterations, including the presence 
of inflammation, edema, fibrosis, and vacuolation of the intima, 
media and adventitia were graded in the same way. In addition, the 
total number of arteries more than 80 J1.ill present in cross-section 
was recorded to assure a similar sampling between animals and 
graded for obliterative arteriopathy (OA). 
Histopathological changes in the liver allografts were evaluated as 
the presence of bile duct damage and/or loss, bile ductular prolifer-
ation, the presence of subendothelial mononuclear infiltration in the 
portal or central veins, and severity of portal tract inflammation. 
I mmunohistopathological Analyses 
Portions of allograft and recipient spleen were sectioned at 4 !J.m 
and stained with a routine indirect avidin-biotin complex method or 
immunofluorescence technique (24). Biotinylated or Cy3-conjugated 
monoclonal antibody (mAb) L21-6 (mouse IgGl)' which reacts with 
the class II MHC antigens of LEW (donor) but not BN (recipient) 
(25), was used to detect donor MHC class II+ cells. The number of 
L21-6+ donor cells was counted in 20 randomly selected high power 
fields (HPF; x 400 magnification). Isotype-matched nonspecific an-
tibody was substituted for mAb L21-6 in negative controls. 
Other mAbs used in this study included R7.3 (a(3TCR), EDI (in-
filtrative macrophages), ED2 (tissue macrophages), anti-rat IgM (B 
cells), OX33 (CD45RA, B cells), OX8 (CD8a), and 8A2 (CDllc, DC). 
Most of these lineage-specific mAbs were conjugated with fluorescein 
(PharMingen, San Diego, CA and Serotec, Kidlington, Oxford, UK). 
For unconjugated mAb, fluorescein-conjugated goat anti-mouse IgG 
was used as a secondary antibody. 
Cell Proliferation and Apoptosis 
Animals were given an intravenous (IV) injection of 50 mg/kg 
5-bromo-2'-deoxyuridine (BrdU, Sigma, St. Louis, MOll hour before 
death. The labeled cells were detected with an anti-BrdU mAb (Am-
ersham Life Science Inc., Cleveland, OH) using routine indirect 
immunoperoxidase staining. The number oflymphocytes undergoing 
DNA synthesis (in S-phaseJ was determined by counting the number 
of BrdU+ lymphocytes in 20 randomly selected HPF (x 400). 
The terminal deoxynucleotidyl transferase-mediated biotin-dUTP 
nick end labeling ITUNELJ method using Apop Tag kit rIntergen, 
Purchase, NY) localized apoptotic cells in the same paraffin blocks 
used for the BrdU DNA synthesis detection. Positively stained cells 
were counted in 20 randomly selected HPF (see above). 
Flow Cytometry 
Splenocytes were prepared by mincing a piece of spleen and lysing 
the red blood cells. Splenocytes were analyzed by two-color flow 
cytometry using affinity purified biotinylated mAbs 163 (rat IgG2b) 
and 42 (rat IgG2a), specific for the RT1.A 1 (LEW MHC class I 
antigen) and the RT1.An (EN MHC class I antigen), respectively (26). 
Cychrome-conjugated streptavidin (PharMingen) was applied as a 
secondary antibody. Lineage-specific fluorescein-conjugated mAbs 
(see above) were used for double stain. 
RNA Preparation and RNase Protection Assay (RPA) 
Total RNA was extracted from frozen samples by using TRIZOL 
Reagent (Life Technologies, Grand Island, NY) according to the 
manufacturer's instructions. The concentration of RNA was deter-
mined by UV spectrophotometer at 260 nm. An RNase protection 
assay (RPA) using commercially available kits (PharMingen) was 
used to quantify cytokine mRNA production. Radiolabeled antisense 
RNA multiple probes were synthesized using in Vitro Transcription 
Kit and rat cytokine multiprobe template sets (rCK-1 and rAPO-I, 
PharMingen), which included probes for cytokines [interleukin (IL)-
la, IL-ll3, IL-2, IL-3, IL-4, IL-5, IL-6, IL-IO, tumor necrosis factor 
(TNF)-a, TNF-I3, and interferon (IFN)'Y]' apoptosis-associated mole-
cules (Fas, FasL, caspase-1, 2, 3, bel-X, bcl-2, and bax), respectively, 
and housekeeping genes (L32 and GAPDH). 
32P-Iabeled probes (8.0x 105 cpm) and sample RNA (5 J.Lg) were 
hybridized at 56°C for 12-16 hours and single-stranded RNAs in-
cluding antisense RNA probes were digested by using RPA Kit 
(PharMingen). The protected RNA duplexe~were isolated by RNase 
inactivation/precipitation solution (Ambion Inc., Austin, TX), and 
electrophoresed in a standard sequencing gel. Dried gels were ex-
posed to Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, 
CAl for 12 hours at room temperature. The radioactivity of each band 
was measured by l3-scan (PhosphorImager, Molecular Dynamics) 
and NIH Image analysis software. The results were normalized to 
GAPDH and expressed as a ratio of cytokine or apoptotic 
signallGAPDH. 
Mixed Lymphocyte Reaction 
One-way MLR assayed antidonor reactivity of BN recipients, in 
vitro (5). Responder cervical lymph node lymphocytes (1.75 x 105) 
obtained from BN recipients 100 days after HTx or OLTx and irra-
diated (2000 rad) stimulator cells (3X105) were combined in a final 
volume of 0.2 mL RPM! supplemented with 25 mM HEPES buffer, 
5X 10-5 M 2-mercaptoethanol, 2 mM L-glutamme, 50 D/ml penicillin, 
50 J.Lg/ml streptomycin, ~-monomethyl-i-arginine-elAc (Cycloapss 
Biochemical Co., Slake Lake, UT) and 10% heat-inactivated normal 
rat serum. Triplicate cultures were incubated in a humidified atmo-
sphere of 5% CO2 in air for 5 days at 37°C. One J.LCi of 3H-thymidine 
was added to each well 16 hours before the termination of the 
culture. Cultures were harvested with multiple sample harvester 
and 3H-thymidine uptake was determined by liquid scintillation. 
Statistical Analysis 
All results were expressed as mean::!:SD. Numbers of positively 
stained cells in tissue sections and mRN A levels in RP A assays were 
analyzed by one-way factorial analysis of variance. Fisher's PLSD 
test assessed the statistical difference between groups. Student's t 
test was used for the analyses of MLR P less than 0.05 was consid-
ered significant. 
RESULTS 
Untreated BN recipients reject LEW heart allografts in 8 
days and LEW livers in 23-32 days (median 28.5), although 
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all liver and heart grafts survive for 100 days under the 
28-day course ofTAC. As reported previously (5), however, by 
100 days (73 days after the last dose of TAC), the liver 
allografts were CR free (Fig. 1, right) although the trans-
planted hearts had severe CR (Fig. 1, left). CR was mani-
fested by endocardial, pericardial, interstititial, and periar-
terial mononuclear inflammation, and by patchy interstitial 
fibrosis. The overall inflammation score (23) was 2.8=1.1. In 
addition, OA was recorded in 53.2% of the vessels examined. 
The liver allografts at day 100 were essentially normal, ex-
cept for mild lymphocytic infiltrates in the portal triad and 
occasional bile duct proliferation indicative of minor biliary 
complications, presumably related to the lack of an arterial 
blood supply (Fig. 1, right). 
The histopathological findings at 100 days posttransplan-
tation were congruent with the results of MLR studies at the 
time of death. Antidonor proliferation of cervical lymph node 
lymphocytes of OLTx recipients was significantly depressed 
(P<O.OOl), although the response of comparable cells from 
100-day heart recipients was much less reduced (P=O.068) 
(Fig. 2). Reactivity against third party strain cells CAC!) was 
fully preserved in both liver and heart recipients. 
Serial Cytokine mRNA Levels 
Previous studies of this liver transplant model demon-
strated that the evolution ofTAC-assisted donor-specific tol-
erance is complete by 4 weeks after which the liver allograft 
remains CR-free without immunosuppression (5, 17). Cyto-
kine profiles were monitored during the 28-day period of the 
immunosuppression. The results were compared with those 
after transplantation under identical treatment of the less 
tolerogenic (that is, CR-prone) heart allografts. 
Levels in the allografts. When no immunosuppression was 
given, IL-2 and IFN'Y were progressively up-regulated in both 
the liver and heart allografts during the first 7 posttrans-
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FIGURE 2. One-way MLR. One hundred days after LEW to 
BN heart and liver transplantation under a 28-day course 
TAC immunosuppression, recipient cervical lymph node 
lymphocytes were stimulated in MLR with irradiated (20 
Gy) LEW (donor), BN (syngenic), and ACI (third party) 
lymphocytes, using cell·free medium as background con· 
trol. The LEW-specific proliferative response shown in the 
third bars of each cluster can be compared with the AeI-
specific (that is, third party) response in the fourth bars. 
Bars 1 and 2 are cell-free medium and syngeneic (EN) stim-
ulator controls. Donor-specific responsiveness was re-
duced significantly in the liver (P<O.OOl vs. normal BN), 
but inconclusively in the heart recipients (P=0.068). 
Liver Graft (daylOO) 
FIGURE 1. Routine histopathology of LEW heart (left) and liver (right) allografts 100 days after transplantation to BN 
recipients under a 28-day course TAC immunosuppression. The liver allograft at day 100 is essentially normal and the heart 
allograft has severe CR, including inflammatory infiltrates, patchy fibrosis, and obliterative arteriopathy. 
106 TRANSPLANTATION Vol. 74, No.1 
plant days, significantly more so in the hearts (Fig. 3, top). 
Smaller increases of 1L-4 and IL-10 were also observed. 
The short course of TAC altered the mixed TH1-TH2 re-
sponse, mainly by down-regulation of signals for IL-2 and 
IFN y that was significantly more pronounced in the liver 
allografts. In addition, a significantly greater increase in 
mRNA for 1L-10 was observed in the TAC-protected liver 
allografts than in the comparable heart allografts (Fig. 3, 
bottom). 
Levels in host spleens. In untreated liver recipients, and to 
a significantly lesser extent in unmodified heart recipients, 
both TH1 (1L-2, 1FNy) and TH2 (1L-4, IL-10) cytokine expres-
sion in the recipient spleens was increased. The directional 
changes were similar to those that occurred in both kinds of 
organ allografts (compare the top of Fig. 4 with the top of Fig. 
3). 
TAC treatment resulted in down-regulation in the host 
spleen of 1L-2 and IFNI' mRNA, significantly more in liver 
than in heart recipients (Fig. 4, bottom). The tripling or 
quadrupling of the TH2 cytokine increases in the spleen (IL-4 
and IL-10) were not different under TAC than in animals 
that were not treated. Of interest, the preferential up-regu-
lation ofIL-10 observed in the liver allografts ofTAC-treated 
recipients was not seen in the spleens of these recipients 
(compare bottom of Figs. 3 and 4). 
Proliferation / Apoptosis 
In the allografts. In untreated recipients, proliferating 
leukocytes (detected by BrdU staining) increased progres-
sively in hearts and livers during the first posttransplanta-
tion week (Fig. 5A, top). The proliferation was strongly asso-
ciated with apoptosis (that is, TUNEL + cells) (Fig. 5B, top). 
However, the apoptotic cells were only one-third to one-half 
as frequent as the BrdU+ cells (compare Fig. 5A and B, 
taking into account the different scales). 
Under TAC, the frequency of the BrdU+ leukocytes rose 
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FIGURE 3. Serial mRNA for cytokines in the allografts: heart 
(open bars) and liver (black bars) (n=3-6 at each time point). 
*P<O.05 (liver vs. heart). N, Normal heart and liver. Upper 
panels, Without immunosuppression, there was dramatic up· 
regulation of THI cytokines (IL-2, IFNl') in both kinds of 
allografts. There also were modest increases (from undetect· 
able) of the TH2 cytokines, IL-4 and IL·IO. Lower panels, 
Under TAC treatment, the THl cytokines were down.regu-
lated, much more in liver than the heart allografts. TH2 cy· 
tokine changes associated with therapy were limited to up· 
regulation of IL·IO in the liver allografts. 
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FIGURE 4. Cytokine mRNA in recipient spleen after heart 
(open bars) and liver transplantation (black bars) (n=3-5 at 
each time point). *P<O.05 (liver va. heart). N, Normal spleen. 
Top, The cytokine changes in the spleen of untreated recipi. 
ents roughly paralleled those in the rejecting heart and liver 
allografts, but were of greater magnitude. (Note the differ· 
ence in amplitude scale of Fig. 4 compared with Fig. 3.) Bot· 
tom, IL-2 and IFNI' expression in the spleen was significantly 
less reduced in TAC-treated heart compared with liver recip. 
ients, but there was no demonstrable effect of therapy on the 
TH2 cytokines. The absence of up·regulation of IL-IO in 
spleen of the liver recipients was inconsistent with the ap-
parent increase of this cytokine observed in the hepatic allo· 
grafts (compare Fig. 4, bottom, with Fig. 3, bottom). 
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FIGURE 5. Numbers of (A) BrdU+ infiltrates and (B) TUNEL + 
cells in allografts on different postoperative days (POD) after 
HTx (open bars) and OLTx (black bars) without treatment 
(top) or under 28-day course of TAC (bottom). n=3-6 at each 
time point. *P<O.05 (heart vs. liver). 
to 28 days (Fig. 5A, bottom). In the heart allografts, these 
cells were mainly in lymphocyte aggregates in the epicar-
dium, pericardium, and periarterial areas. The number of 
TUNEL + (apoptotic) cells increased in rough parallel to the 
BrdU+ cells and at two time points (days 1 and 14), the 
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apoptotic cells were significantly more numerous in liver 
than in heart grafts (Fig. 5B, bottom). 
With or without immunosuppression, mRNA for Fas and 
caspase-3 were significantly more up-regulated in liver than 
in heart allografts at most time points (Fig. 6). 
In host spleens. At day 5 in untreated OLTx recipients, the 
BrdU+ cells rose in the recipient spleens to a peak of 
365±28.4 cellslHPF, more than twice the number in the 
spleens of the heart recipients (Fig. 7 A, top). After both liver 
and heart transplantation, the BrdU+ cellslHPF were 5 to 10 
times more numerous in the host spleen than the respective 
allografts [compare Fig. 7 A, top (spleen), with Fig. 5A, top 
(allograft)]. 
Under TAC therapy, the burst of BrdU+ cells in the host 
spleen after liver as well as heart transplantation was 
blunted or reversible. The number of positive cells remained 
elevated throughout the 28 days of immunosuppression (Fig. 
7 A, bottom). In parallel with the BrdU+ leukocytes, a smaller 
number of TUNEL + (apoptotic) cells were observed in the 
host spleen after both kinds of transplantations, similar to 
the BrdU+ !I'UNEL + proportions in the allografts (compare 
Fig. 7B, bottom, with Fig. 5B, bottom). The apoptotic cells in 
both the host spleen (Fig. 7B, bottom) and the transplanted 
organ (Fig. 5B, bottom) was greater when the allograft was a 
liver (significant on days 1 and 14). This observation was 
supported by the RPA ofmRNA for apoptosis-associated mol-
ecules that showed greater up-regulation of apoptotic signals 
in the spleens of TAC-treated liver recipients (Fig. 8). The 
latter confirmatory evidence was weakened by the limitation 
of this finding to day 14. 
Immunohistopathological Studies of Host Spleen 
Donor MHC class Ir (L21-6+) cells. After HTx, less than 
0.25 donor MHC class II+ cellslHPF were detected in the red 
pulp, peri arteriolar lymphoid sheath (PALS), and marginal 
zone of the spleen, regardless of TAC administration (data 
not shown). In contrast, many more donor MHC class II+ 
cells were found in the recipient spleen after liver transplan-
tation. At 1 and 3 days, the number and location of these cells 
was the same with or without TAC treatment. Donor class 
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FIGURE 6. RP A of mRNA for Fas, Fas-L, and caspase-3 in heart 
(open bars) and liver allografts (black bars) without treat-
ment (upper panels) or under a 28-day course of TAC (lower 
panels). n=3-6 at each time point: *P<05 (liver vs. heart). 
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FIGURE 7. Numbers of (A) BrdU+ and (B) TUNEL + cells per 
high power field (x 400) in recipient spleen on different post-
operative days (POD) after HTx and OLTx; compared with 
findings in allografts (Fig. 5). Recipients were either un-
treated (top) or treated with short course of TAC (bottom). 
Both BrdU+ and TUNEL + cells increased in untreated recip-
ients. Under TAC, liver recipients show sustained increases 
of proliferation and apoptosis. n=3-6 at- each time point. 
*P<O.05 (liver vs. heart). 
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FIGURE 8. RPA ofmRNA for apoptotic signals in the spleen of 
heart and liver recipients without treatment (top) or under a 
short course of TAC (bottom). Compare with findings in Fig-
ure 6. n=3-6 at each time point. *P<O.05 (liver vs heart). 
II+ cells disappeared from the spleen of untreated animals by 
7 days. In TAC-treated liver recipients (Fig. 9), the mean 
numbers of donor MHC class II+ cells were 13.0, 11.8, 1.7, 
and 1.1 cellslHPF at 1, 3, 7, and 14 posttransplant days, 
respectively. 
The donor MHC class II+ cells localized predominantly to 
the periphery of the splenic PALS and marginal zone by 1 
day after transplantation although a small number was also 
found within the PALS. Donor MHC class II+ cells disap-
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FIGURE 9. Number of donor (LEW) MHe class n+ (L21-6+) 
cells in the BN host spleen after liver transplantation. Far 
fewer donor MHe class 11+ cells are found after heart trans· 
plantation (23). Mean:tSD of three to seven animals at each 
time point. 
peared from the marginal zone during the next 7 days al-
though a few persisted in the PALS for 28 days. 
Double immune fluorescence. Double staining with mAb 
L21-6 and anti-rat IgM or OX33 (CD45RA) showed that 
L21-6+/IgM+ donor B cells and other donor MHC class II+ 
cells localized mainly to the B-cell follicle and marginal zone 
of the recipient spleen after OLTx (Fig. 10, A and B). Double 
staining for macrophages (ED1, ED2) excluded the possibil-
ity of significant donor macrophage migration to the recipient 
spleen (Fig. 10, C and D). The few donor MHC class II+ cells 
localizing to T cell areas (mAb R7.3+, a,BTCR+) (Fig. 10, E 
and F) were also positive for CDllc (8A2), indicative of donor 
MHC class II+ DC (Fig. 10, G and H). Although expression of 
CD8a correlates with differences in lineage origin and func-
tion activity of DC (27), only a few donor DC expressed CD8a. 
This suggests that donor DC migrating into the recipient 
spleen after OLTx are a mixture of "myeloid" and "lymphoid" 
DC (Fig. 1OI). 
Flow Cytometry of Spleen Cells 
Because the foregoing studies were limited to donor MHC 
class II+ cells, they grossly underestimated the total donor 
cell load delivered to the spleen. To obtain a rough estimate 
of the true migratory leukocyte traffic relative to the MHC 
class II+ subset, spleen cell suspensions were analyzed by 
flow cytometry using antidonor/recipient MHC class I mAbs 
after both HTx and OLTx. With or without treatment, donor 
cells could not be reliably detected by flow cytometry in the 
recipient spleen at any time point after HTx (data not 
shown). 
Without TAC treatment, donor cells disappeared from the 
spleens ofliver recipients by 7 days. Under TAC, donor MHC 
class 1+ cells accounted for 1 to 5% of splenocytes between 1 
to 14 days after OLTx (Fig. 11). The donor cells at 7 days in 
the treated animals were mainly a!3TCR+ (50-70%), but NK 
and B cells also were identified. 
DISCUSSION 
It is known that donor passenger leukocytes leave the 
allograft after organ transplantation (28-30) and migrate 
preferentially at first to host lymphoid organs (17, 24, 31,32). 
They induce an adaptive immune response that may proceed 
to variable degrees of apoptosis-associated (33) clonal ex-
haustion-deletion (1-4, 34), the maintenance of which is de-
pendent on the continued presence of the mobile donor cells 
(1, 2). Survival of small numbers of these donor passenger 
leukocytes is facilitated by their secondary migration to "pro-
tected" nonlymphoid sites including the organ allograft (35-
37), from where they may pass back to host lymphoid organs 
and maintain the donor-specific clonal exhaustion-deletion 
induced at the outset (1, 2). 
In this paradigm, the key event in determining immune 
responsiveness or nonresponsiveness to an organ is leukocyte 
migration and localization. Consequently, the variable post-
transplant events are best understood in terms of dose and 
localization of the mobile antigen, and particularly the time 
during which this alloantigen is in host lymphoid organs (1, 
2). The serial changes in proliferationiapoptosis indices in 
our experiments suggest that the immune activation-depen-
dent mechanisms that result in the evolution of variable 
levels of immunosuppression-assisted deletional tolerance 
and engraftment differ only in degree after liver and heart 
transplantation. The proliferation response induced by the 
highly tolerogenic liver exceeded that induced by the weakly 
tolerogenic heart. The differences in outcome were explicable 
by the far greater load of immunostimulatory passenger leu-
kocytes contained in hepatic allografts, and by the persis-
tence of more of these cells in the liver recipients. 
In this interpretation, the changing cytokine profiles ob-
served were downstream effects of unmodified or immuno-
suppression-altered immune activation, rather than imply-
ing any self-sustaining immunoregulatory role in organ 
engraftment of the cytokines per se, singly or in combination. 
One of the immune regulation hypotheses holds that the 
absence of the TH1 type cytokines CIL-2 and IFN')') and 
the presence of TH2 type cytokines (IL-4 and IL-10) lead to 
the CR-free organ transplant acceptance (38-40). This has 
not been supported by molecular studies of cytokine mRNA of 
human renal allografts or by observations in several animal 
models (41). We have suggested instead that alloengraftment 
is an active process whose perpetuation requires the persis-
tence of donor leukocytes (1,2). 
Our specific question was whether there was any his-
topathological evidence in the host spleen suggesting a 
unique role of particular lineages of the donor leukocytes, 
either in eliciting rejection or inducing tolerance. The ques-
tion was prompted in part by the results of a recent study by 
Ichikawa et a1. (35) in which the percentages and lineages of 
donor leukocytes in cell suspensions prepared from test LEW 
heart allografts and host spleens were determined after their 
transplantation to drug-free BN recipients who had variably 
tolerized 100 days previously by LEW heart, bone marrow 
cell, or liver transplantation under the standard 28-day 
course of TAC. In these earlier studies, flow cytometry anal-
yses and parallel histopathological-immunocytochemical 
findings showed that the failure of CR to develop in the 
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FIGURE 10. Immunofluorescence stain of donor MIIC class 11+ cells. Double immunflourescence stain using mAb L21-6 (LEW 
MIIC class II) in all panels with a variety of lineage-specific mAbs. Donor MIIC class 11+ cells stained only with L21-6 are red. 
Cells stained only with lineage specific mAb are green. Double-stained cells are yellow. (A) Rat IgM stain of B-cell follicle 
surrounded by marginal zone. The vacant area (right) is periarteriolar lymphoid sheath (PALS). Note the dense concentration 
of donor B cells (yellow) within the follicle, and a few probable DC (red) in the periphery of PALS (x 200). (B) Higher power 
offollicle-P ALS junction shown in A (x 400). (C) ED1 single-stained macrophages (green) in the red pulp outside the periphery 
of the marginal zone with single-stained L21-6+ cells in the heart of the B-cell follicle (x 200). (D) ED2 single-stained 
macrophages (green) in the red pulp. The B-cell follicle has been moved more to the right than in C (x 200). (E) Single-stained 
a/:lTCR+ T cells (probably host) in PALS (right) with numerous L21-6+ (donor) B cells in the follicle and two L21-6+ cells 
(presumably DC) in PALS (x 200). (F) Higher power of E showing the two probable DC in PALS (x 400). (G) Double-stained 
[L21-6+ and 8A2 (CDllc+)] DC in PALS and numerous L21-6 single-stained donor B cells in the adjacent B-cell follicle (x 200). 
(H) Higher power of G (x 400). (I) A few double-stained cells [L21-6+ and OX8+ (CD8a)] thought to be lymphoid DC in the PALS 
with a few adjacent single-stained L21-6+ cells (x 200). 
challenge hearts correlated more directly with the total 
quantity of donor leukocytes in the challenge cardiac allo-
grafts and the spleens of the primed host than with the small 
subset of MHC class II+ donor leukocytes that included DC 
(35). 
Because MHC class II+ cells function as antigen present-
ing cells (APC) and because DC can prime T cells in vitro, it 
has been assumed that DC constitute the truly immunogenic 
subset of passenger leukocytes (19-21, 42). Neither our find-
ings in the spleens of recipients of primary liver allografts 
nor the related observations of Ichikawa et al. (35) formally 
eliminate the possibility that donor DC playa crucial role in 
graft outcome. Our data are not consistent with a lineage-
specific hypothesis to explain either organ rejection or allo-
engraftment. During the first 2 weeks after liver transplan-
tation, donor cells accounted for 1 to 5% of the host spleen 
leukocytes. Most of these donor cells were class II- (that is, 
50-70% were T cells). The smaller population of MHC class 
II+ donor leukocytes was made up principally of B cells with 
only a very small proportion of myeloidllymphoid DC. 
Most of the donor B cells migrated to the B-cell areas ofthe 
recipient spleen where (as expected) direct contact and ag-
gregation of host T cells around donor B cells could not be 
demonstrated by double labeling. The few donor DC were 
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FIGURE 11. Two-color flow cytometric analysis of splenocytes using mAbs 163 (LEW MHC class I), 42 (BN MHC class I), and 
L21-6 (LEW MHC class 11), and lineage-specific mAbs OX 33 (B cells), R7.3 (aIITCR), and NK323 (NK cells). Splenocytes were 
obtained 7 days after LEW to BN OL Tx under TAC immunosuppression. Representative experiment performed in four 
animals (see text). 
limited to the splenic PALS, in contiguity with T cells (see 
Fig. 10). Despite their strict localization to the splenic T cell 
area, it was not possible with our methodology to identify the 
aggregation of host T cells around donor DC that has been 
ascribed to "direct allorecognition" or "direct alloactivation." 
Thus, it remains unclear whether the donor MHC class II+ 
cells that reached splenic T-cell areas triggered host T cells 
directly or whether the alloantigens were presented as class 
II- (or class 1) derived peptide to T cells via host APC by the 
classical "exogenous" indirect pathway (43) that has been 
increasingly associated with chronic (as opposed to acute) 
rejection (19, 20, 44-46). 
It is widely believed that allorecognition of and direct im-
mune activation by highly immunogenic passenger leuko-
cytes is responsible for acute rejection (20, 42, 44, 47). This 
hypothesis has been questioned by studies suggesting that 
acute rejection is largely, if not exclusively, by the indirect 
pathway (48-51). Whether and how peptide derived from the 
donor passenger leukocytes is captured and processed by the 
host APC via the indirect pathway is unclear. 
Finally, the unique immunogenicity, of the passenger leu-
kocytes has been ascribed to special qualities of DC, e.g., the 
expression of MHC class II or costimulatory molecules such 
as B7 (20,52,53). We studied the possibility that passenger 
leukocytes are immunogenic mainly because they can mi-
grate to lymphoid organs although parenchymal cells osten-
sibly lack immunogenic properties simply because they are 
immobile and cannot reach these lymphoid destinations (2, 
35). If this is correct, the quantity rather than the lineages of 
the passenger leukocytes is the key factor in initiating the 
immune activation that may lead to acute rejection, or pro-
ceed to clonal exhaustion-deletion and variable tolerance. 
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